trending Market Intelligence /marketintelligence/en/news-insights/trending/isFbj7O5u42INNNtBmUVZA2 content esgSubNav
In This List

Melinta Therapeutics interim CEO to assume permanent role

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Melinta Therapeutics interim CEO to assume permanent role

Melinta Therapeutics Inc. said John Johnson agreed to become the company's permanent CEO.

Johnson, who is a director of the New Haven, Conn.-based pharmaceutical company, has served as interim CEO since Oct. 22. He filled in for Dan Wechsler, who stepped down to pursue other opportunities.

The appointment is subject to the close of a previously announced commitment for a credit facility of up to $135 million from its largest shareholder, Vatera Healthcare Partners LLC.